US6987171B1 - Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes - Google Patents
Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes Download PDFInfo
- Publication number
- US6987171B1 US6987171B1 US09/449,077 US44907799A US6987171B1 US 6987171 B1 US6987171 B1 US 6987171B1 US 44907799 A US44907799 A US 44907799A US 6987171 B1 US6987171 B1 US 6987171B1
- Authority
- US
- United States
- Prior art keywords
- cells
- human
- monoclonal antibodies
- specific
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract description 50
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 title abstract description 38
- 230000004913 activation Effects 0.000 title description 15
- 210000004408 hybridoma Anatomy 0.000 claims description 21
- 241000282414 Homo sapiens Species 0.000 abstract description 20
- 102000006306 Antigen Receptors Human genes 0.000 abstract description 11
- 108010083359 Antigen Receptors Proteins 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 57
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 50
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 48
- 238000004519 manufacturing process Methods 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 102000004388 Interleukin-4 Human genes 0.000 description 8
- 108090000978 Interleukin-4 Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008105 immune reaction Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000000284 resting effect Effects 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 210000001938 protoplast Anatomy 0.000 description 4
- 230000036647 reaction Effects 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000001926 lymphatic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000750676 Bacillus phage Gamma Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000819111 Homo sapiens Trans-acting T-cell-specific transcription factor GATA-3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 description 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100021386 Trans-acting T-cell-specific transcription factor GATA-3 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Definitions
- the invention in question is concerned with monoclonal antibodies which are specific for human CD28 and activate T-lymphocytes without occupancy of an antigen receptor of the T-lymphocytes, i.e. antigen-non-specific, hybridoma cells for the production of such antibodies, a procedure for the production of such antibodies and applications of such antibodies.
- Monoclonal antibodies is the term for antibodies which are produced by hybrid cell lines (so-called hybrido-ma), which have resulted from a fusion of a B cell of animal or human origin producing antibodies with a suitable myelom tumour cell.
- CD28 designates a cell surface module of a known amino-acid sequence expressed on T-lympho-cytes of human and animal origin, to which the abbreviation CD28 was given in the course of the international “Human Leukocyte Typing Workshops”.
- T-lymphocytes an increase in metabolic activity, enlargement of the cell volume, synthesis of immunologically important molecules and the start of cell division (proliferation) of T-lymphocytes upon an external stimulus is meant.
- these processes are initiated by the occupancy of the CD28 molecule on T cells by certain CD28-specific monoclonal antibodies.
- the activation of T-lymphocytes with the peripheral phenomena described is a part of the physiological immune reaction, but can get out of control there (lympho-proliferative diseases) or be insufficient (immune deficiency) in pathological situations.
- the activation of resting T cells for proliferation and functional differentiation firstly demands the occupancy of two surface structures, so-called receptors: 1. the antigen receptor, which possesses a differing specificity from cell to cell and is necessary for the recognition of antigens, e.g. viral fission products; and the CD28 molecule expressed on all resting T cells to the same extent, which naturally binds on ligands on the surface of other cells of the immune system.
- receptors e.g. viral fission products
- CD28 molecule expressed on all resting T cells to the same extent, which naturally binds on ligands on the surface of other cells of the immune system.
- CD28-specific monoclonal antibody produced by conventional means, i.e. by immunisation of mice with human T cells, can activate a sub-group of human T cells in cell culture without occupancy of the antigen receptor for proliferation if CD28 is occupied by this monoclonal antibody and the cell-bound monoclonal antibody molecules are additionally crosslinked with one another by further antibodies.
- the antibodies described are firstly not principally suited for use in human medicine, as they are mouse antibodies. Further, the two described antibodies have the common point that only a very small part of the T cells can be activated “directly”.
- CD28-specific monoclonal antibodies with varying functional properties were described: “classical antibodies”, which only co-stimulate the activation of resting T cells with the simultaneous occupancy of the antigen receptor; and “direct” ones, which can activate T-lymphocytes of all classes in vitro and in animals to proliferation without occupancy of the antigen receptor.
- monoclonal antibodies known in this regard come from an immunisation with cells on which rat CD28 is expressed and are available by various selections aimed at the properties described for each of them.
- CD28-specific monoclonal antibodies possessing the directly activating effect bind on T-lymphocytes much more slowly than classical CD28-specific monoclonal antibodies; the binding on a mouse fibroblast cell line (L-929), on the surface of which the CD28 molecule is artificially expressed by transfection, takes place for classical and “directly” stimulating CD28-specific monoclonal antibodies at the same speed.
- the “directly” stimulating CD28-specific monoclonal antibodies known in this regard recognise an active form of the CD28 molecule, the existence on which on resting T cells is suppressed by a mechanism as yet unknown, but which is accessible in expression of the molecule in non-T tumour cell lines.
- the monoclonal antibodies known in this regard are on the one hand specific against rat CD28, on the other hand mouse antibodies. They are therefore not suitable for therapeutic purposes in man for both reasons.
- the invention in question is based on the technical problem of making “direct” human-CD28 specific monoclonal antibodies available which on the one hand are human-compatible and on the other hand are able to activate human T cells to a large extent.
- the invention in question teaches human-compatible monoclonal antibodies which are specific for human CD28 and human T-lymphocytes of several to all sub-groups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically, preferably with human constant components.
- Constant components of an antibody are areas which are not of importance for the recognition of an antigen, as opposed to the variable areas, which define the antigen-specificity of an antibody. Constant components however differ in antibodies of various kinds and consequently also animals and humans.
- the constant areas of an antibody must correspond to those of antibodies of an organism which is to be treated with the antibodies in order to be compatible.
- Monoclonal antibodies in accordance with the invention are therefore human-compatible on the one hand, be it per se or by humanisation, and can on the other hand be used to treat various diseases which are based on an excessively low T-lymphocyte activity, as the antibodies are specific against human CD28 and as the activation of the T-lymphocytes is extensive.
- the invention in question naturally includes various derivatives of monoclonal antibodies provided the features stated in the claims are fulfilled.
- Derivatives of monoclonal antibodies means modifications of the monoclonal antibodies which are generated by customary biochemical or gene-technical manipulations. This exists, for example, in the humanisation of monoclonal antibodies of a mouse through partial substitution of structural (constant) components of the mouse antibody through those of a human one.
- monoclonal antibodies according to the invention are available through: A) production of hybridoma cells enabled to produce monoclonal human-CD28 specific animal antibodies by means of an immunisation with non-T tumour cell lines on which human CD28 is expressed, B) if applicable, humanisation of the monoclonal animal antibodies available from the hybridoma cells pursuant to phase A through a biochemical or gene-technological exchange of constant components of the animal antibodies against analogous constant components of a human antibody or replacement of genes of the hybridoma cells corresponding to the components; C) secreting of the antibodies in hybridoma cell cultures and isolation of the antibodies from it or production of the antibodies by injection of the hybridoma cells into animals, for example mice, and isolation of the antibodies from the body fluid of the animal.
- the core of the invention entails the knowledge that a “direct” activation of practically all the T-lymphocytes can be achieved if the monoclonal antibodies are obtained by immunisation with non-T tumour cells on which human CD28 is expressed instead of an immunisation with T cell lines. In this way, monoclonal antibodies can be obtained which are not only specific against human CD28, but also cause a “direct” activation to a considerable extent.
- monoclonal antibodies according to the invention have specificity for determinants of the human CD28 molecule, which are difficult to access on the naturally expressed CD28 molecule and the occupancy of which by the new kind of monoclonal antibodies leads to an activation of the T cells.
- a determinant means the area of a molecule which is defined by the binding specificity of one or more antibodies.
- the hybridoma cells enabled to produce monoclonal human-CD28 specific animal antibodies are available through a) creation of a plasmid by means of insertion of human-CD28 cDNA into the pHOAPr-1-neo vector following excision of the SaII-HindIII fragment and production of protoplasts from Escherichia coli (MC1061) which carry the plasmid, b) fusing of the protoplasts with mouse A20J and/or L929 tumour cells by means of polyethylene glycol, c) cultivation of the transfected cells received in phase b, d) screening of the transfected mouse A20J and/or L929 cells for the expression of human CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28, e) immunisation of BALB/c mice with mouse A20J and/or L929 cells expressing human-CD28 (for example by injection 6 ⁇ i.p.
- the pH ⁇ APr-1-neo vector is freely available from the authors of the literature Gunning, P., et al., 1987, “A human ⁇ -actin expression vector system directs high-level accumulation of antisense transcripts”, Proc. Natl. Acad. Sci. USA, 84:4831. In this. “neo” stands for neomycin resistance. Phase c) is therefore carried out with the presence of neomycin.
- the cell lines and/or micro-organisms mentioned above are freely available and can be purchased from the American Type Culture Collection (ATCC).
- ATCC American Type Culture Collection
- Escherichia coli (MC1061) supplementary reference is made to the literature Meissner, P. S., et al., 1987, “Bacteriophage gamma cloning system for the construction of directional cDNA libraries”, Proc. Natl. Acad. Sci. USA, 84:4171.
- the object of the invention also includes, hybridoma cells as well as a procedure for the production of antibodies.
- the use of monoclonal antibodies according to the invention for the production of medicines in particular the treatment of diseases with pathologically reduced CD4-T cell figures, such as AIDS or in stem cell transplantations following chemotherapy of leukemic diseases, for potentiating and/or qualitative influence of immune reactions in protective inoculations and/or in order to influence the quality of T cell reactions, in particular to influence the production of various effector molecules, for example cytokines and chemokines and their receptors, e.g. in auto-immune diseases and AIDS, is of independent importance.
- the galenic production of the medicines for the various forms of administration is well known to experts and need not be explained in more detail here.
- the quality of the T cell reaction is in particular to be understood as the production of certain cytokine patterns, which can, for example, be effective in a pro or anti-inflammatory way or can selectively lead to the production of certain classes of immunglobulin in B lymphocytes (classic examples of differing qualities of the T cell reaction are the function TH1 and TH2 phenotypes, as described below in examples),
- the invention also entails procedures for the healing of the diseases mentioned both above and below, making use of monoclonal antibodies according to the invention.
- CMY-2 monoclonal antibodies according to the invention. They are also termed below as CMY-2.
- Human CD28 from a cDNA library was recombinantly expressed in A20J and/or L929 cell lines.
- a plasmid was created by means of insertion of human-DC28 cDNA into the pH ⁇ APr-1-neo vector following excision of the SalI-HindIII fragment.
- Protoplasts, which carry the plasmid were produced from Escherichia coli (MC1061). There was then a fusing of the protoplasts with mouse A20J and/or L929 tumour cells by means of polyethylene glycol.
- transfected cells obtained in this way were cultivated in the customary way. There was then a screening of the transfected mouse A20J and/or L929 cells for expression of human-CD28 and selection of mouse A20J and/or L929 cells expressing human-CD28.
- the A20J human-CD28 cell line was used for the immunisation of BALB/C mice.
- Cell fusion and screening were carried out as follows: i) immunisation of BALB/c mice with the mouse A20J cells expressing the human-CD28 (injections 6 ⁇ i.p. and then 1 ⁇ i.v.). ii) Removal of spleen cells of the mice immunised in this way and fusing of the spleen cells with cells of the X63-Ag 8.653 cell line by means of polyethylene glycol. iii) Selection of the hybridoma cells obtained in this way with the condition that in the supernatant of selected hybridoma cells there are antibodies contained which bind on mouse A20J and/or L929 cells expressing human-CD28.
- the read-out was the staining of a mixture of CD28 transfected and untransfected L929 tumour cells.
- FIG. 2 shows that the CMY-2 monoclonal antibody isolated in this way distinguishes transfected and untransfected cells by differences in the fluorescence intensity.
- the differential screening for antibodies against human-CD28 was done as follows. 50 ⁇ l each of supernatant of cultivated cell hybridoma were removed and incubated for 15 min with a mixture of L929 cells and L929-CD28 transfectants. After washing, the cells were stained with DaMIg-PE. Part A shows the negative check. The cells were only incubated with DaMIg-PE. Part B shows the coloration with a supernatant which was slightly positive, but shows no difference in the two cells. Part C shows the cells stained with a supernatant of CMY-2.
- peripheral blood cells of man were stained with the newly isolated CMY-2 and the “classical”, CD28-specific antibody 9.1. An identical expression pattern was found on the sub-populations of human blood cells.
- CMY-2 is a human CD28-specific antibody.
- CMY-2 was then tested with human T-lymphocytes from peripheral blood enriched to about 80% for classical co-stimulating and for “directly” stimulating activity.
- the T cell proliferation was measured by adding 3 H-thymidin between the 2 nd and 3 rd day of the culture. The following results were achieved:
- Co-stimulation Unstimulated cells 276 cpm CD3-specific antibodies 3111 cpm CD3-specific antibodies + CMY-2 51676 cpm
- Direct stimulation Solid-phase anti-mouse Ig 379 cpm Solid-phase anti-mouse Ig + control mAk 258 cpm Solid-phase anti-mouse Ig plus CMY-2 19115 cpm
- CMY-2 ensures T cell receptor stimulation (CD3 is a part of the TCR complex).
- CMY-2 was used in the form of an uncleaned culture supernatant (50% final volume).
- the effective mAk concentration to be expected is sub-optimal for a direct activation, but sufficient for the co-stimulation.
- the experiment shows that CMY-2 has directly activating properties.
- Hybridoma cells according to the invention which produce CMY-2 have been deposited with the DMSZ, the German Collection of Micro-organisms and Cell Cultures, Mascheroder Weg 1b, D-38124 Braunschweig, under number DSM ACC2533 on may 20, 1998.
- IL-4 is decisive for the cooperation of the TH2 cells with B lymphocytes, for the differentiation of further CD4 T cells to TH2 cells and thus the polarisation of the immune system away from the inflammation and towards the humoral immune reaction
- IL-10 is the central factor for the suppression of inflammatory (TH1) reactions. Only the more important results of the in vivo treatment of rats have been portrayed. In vitro, even clearer effects were found.
- FIG. 3 shows the expressed cytokine profile of lymphatic nodes and spleen cells of young LEW rats three days after i.p. injection of the directly activating mAk JJ316, the co-stimulator JJ319, the TCR-specific mAk R73 or the vehicle PBS.
- the figure shows a so-called RNAse protection test, in which radioactively marked antisense mRNA samples are protected against the decomposition of added RNAse. These go onto bands defined on the gel and make it possible to have a good overview of the expressed cytokine profile on the mRNA level of a tissue at a glance.
- the two smallest fragments, L32 and GADPH, are “household genes”, the identical expression of which is used for the check of equally large amounts of RNA used in the individual cases.
- the test was carried out with a kit commercially available from the firm of Pharmingen.
- JJ316 not JJ319 or R73, massively induce IL-10 and, to a lesser extent, IL-4 mRNA.
- the effects are especially clear in the spleen, but are also visible in lymph nodes.
- the cytokine IL-4 on a protein and simultaneously on a single-cell level is proven by flow-cytophotometric analysis.
- the cells are firstly stained with mAk against the surface molecule CD4, then fixed and made permeable, with the result that the IL-4 protein can be proven in a subsequent cytoplasmatic staining with an IL-4-specific mAk which is marked with a second fluoride chrome.
- the evaluation is done in a flow-cytophotometer, each point representing a cell.
- the quadrants inserted represent the borders between the background and a positive reaction. The methods are also described in great detail in the catalogue of the firm of Pharmingen.
- FIG. 4 shows, the injection of the mAk JJ316, but not that of the classical costimulator JJ319, induces the production of IL-4 in a substantial share of the isolated CD4 T cells.
- FIG. 5 a biological effect of the increased IL-4 production is shown: the level of detectable antibodies of the IGE class clearly rises as a result of the treatment with mAk JJ316 and proves the in vivo effectivity of the IL-4 secretion induced by “direct” CD28-specific monoclonal antibodies.
- FIGS. 6 and 7 show so-called EMSAs (Electrophoretic Mobility Shift Assays) as a proof of the induction of transcription factors which support the development of anti-inflammatory TH2 cells.
- the technique is as follows. T cells are stimulated in vitro for differing lengths of time, then the proteins from the cell cores are put into solution and incubated with a radioactively marked short gene probe, the sequence of which they should recognise as transcription factors. After the incubation, the mixture is separated on a poly-acrylamide gel. The unbound marked gene probe exudes from the gel at the bottom (cannot be seen here). Bands such as those portrayed here are partly non-specific (exist everywhere) or are selectively induced (strong, weak signals, depending upon the stimulus).
- the interconnections for the immune-regulatory and immune-modulating effect of “direct” CD28-specific monoclonal antibodies with regard to the formation of TH1 and/or TH2 cells explained above in detail consequently make them especially suited for the production of medicine for the treatment of such immune reactions of independent diseases. Principally, these are all the allergic-inflammatory and auto-immune-inflammatory clinical pictures.
- the former include, for example, the inflammatory diseases of the intestines summarised under the designation “Inflammatory Bowel Disease” (IBD) and contact dermatitis.
- IBD Inflammatory Bowel Disease
- the latter includes Type I diabetes and multiple sclerosis.
- IBD Inflammatory Bowel Disease
- a strong stimulation of the human CD28 molecule by monoclonal antibodies according to the invention will be in a position to cure T cells infected by HIV I. In this way, chemokine receptors used by the viruses as cellular co-receptors can be eliminated an the production of chemokines, which bind on such receptors
- FIG. 8 shows the proliferative reaction of unseparated lymphatic node cells of rats to the “directly” stimulating CD28-specific monoclonal antibody (JJ316) and the lack of such a reply in the use of a “classical” CD28-specific monoclonal antibody (JJ319).
- the cells were cultivated for 2 days in 0.2 ml of medium (RPMI 1640, available for GIBCO/BRL, containing 5% FCS [fetal calf serum]) in presence or absence of the above mentioned additives with a density of 1 million cells per ml in a gassed incubator.
- the cell division activity was determined by the addition of radioactively marked thymidin (1 ⁇ Ci/insertion for 16 hours, 1 Ci-37 GBq, determination with ⁇ detector).
- FIG. 9 shows this for lymphatic nodes in rats which had been given 1 mg of the “directly” stimulating CD28-specific monoclonal antibody (JJ316) or of the “classical” CD28-specific monoclonal antibody (JJ319) on day 0.
- directly activating monoclonal antibodies according to the invention with a specificity for human-CD28 and their ability to stimulate the proliferation of T-lymphocytes, totally analogous effects were achieved. This can then be particularly applied in situations in which the share of CD4 T cells has been pathologically reduced and is to be brought back up towards the normal level again.
- CD4 T cells are only temporarily increased; this is due to the fact that healthy animals were treated with normal CD4 T cells.
- the “surplus” cells resulting from the proliferation stimulation are reduced by homeostatic mechanisms.
- FIG. 10 shows an experiment on this for the so-called Adjuvans Arthritis in rats, a model system for certain forms of rheumatoid arthritis in humans.
- “Paw volume increase” shows the increase in the volume of the paw.
- “Healthy” data points show figures for healthy animals.
- AA stands for Adjuvans Arthritis.
- PBS stands for “Phosphate-buffered saline”.
- W3/25 stands for a monoclonal antibody with specificity for the CD4 molecule of rats.
- the Adjuvans Arthritis is mediated by so-called TH1 cells.
- TH1 cells result from resting CD4 T cells in the course of the activation under the influence of certain soluble factors of the immune system, so-called cytokines.
- the counterparts of the TH1 cells are the TH2 cells, which have an antiinflammatory effect and the induction of which is controlled by other cytokines.
- FIGS. 10 and 11 the induction of the Adjuvans Arthritis was almost completely suppressed by the “directly” activating CD28-specific monoclonal antibody JJ316, measured on the joint swelling ( FIG.
- the “classical” CD28-specific monoclonal antibody (JJ319) had the opposite effect, i.e. it deteriorated the clinical picture. From this, it can be seen, also for use in humans, that the immune reaction can be influenced by the application of conventional or “directly” stimulating CD28-specific monoclonal antibodies according to the invention, here in the sense of an “immune deviation” to TH1 or TH2.
- monoclonal antibodies according to the invention but also “classical” monoclonal antibodies which are specific for human-CD28 (and/or are available by immunisation with T cells) cause an immune modulation. Such a purpose of application of “classical” monoclonal antibodies is also not known.
- the invention also affects the use of monoclonal antibodies specific against human-CD28 (available according to the above mentioned principal modes of procedure in immunisation with T cell lines or non-T cell lines expressing human-CD28) for the production of medicines for the modulation of immune reactions, viz. immune suppression (for example with human-CD28 analogues to JJ319) or immune reinforcement (for example with human-CD28 analogues to JJ316 such as CMY-2).
- immune suppression for example with human-CD28 analogues to JJ319
- immune reinforcement for example with human-CD28 analogues to JJ316 such as CMY-2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Co-stimulation: | ||||
Unstimulated cells | 276 | cpm | ||
CD3-specific antibodies | 3111 | cpm | ||
CD3-specific antibodies + CMY-2 | 51676 | cpm | ||
Direct stimulation: | ||||
Solid-phase anti-mouse Ig | 379 | cpm | ||
Solid-phase anti-mouse Ig + control mAk | 258 | cpm | ||
Solid-phase anti-mouse Ig plus CMY-2 | 19115 | cpm | ||
Claims (1)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/019,530 US20060039909A1 (en) | 1997-05-28 | 2004-12-23 | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
US12/756,665 US8334102B2 (en) | 1997-05-28 | 2010-04-08 | Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19722888A DE19722888A1 (en) | 1997-05-28 | 1997-05-28 | Human CD28 specific monoclonal antibodies for antigen-unspecific activation of T lymphocytes |
PCT/DE1998/001499 WO1998054225A2 (en) | 1997-05-28 | 1998-05-28 | Human-cd28 specific monoclonal antibodies for antigen non-specific activation of t-lymphocytes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1998/001499 Continuation WO1998054225A2 (en) | 1997-05-28 | 1998-05-28 | Human-cd28 specific monoclonal antibodies for antigen non-specific activation of t-lymphocytes |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/019,530 Division US20060039909A1 (en) | 1997-05-28 | 2004-12-23 | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
US6987171B1 true US6987171B1 (en) | 2006-01-17 |
Family
ID=7831064
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/449,077 Expired - Fee Related US6987171B1 (en) | 1997-05-28 | 1999-11-24 | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
US11/019,530 Abandoned US20060039909A1 (en) | 1997-05-28 | 2004-12-23 | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
US12/756,665 Expired - Fee Related US8334102B2 (en) | 1997-05-28 | 2010-04-08 | Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/019,530 Abandoned US20060039909A1 (en) | 1997-05-28 | 2004-12-23 | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
US12/756,665 Expired - Fee Related US8334102B2 (en) | 1997-05-28 | 2010-04-08 | Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes |
Country Status (6)
Country | Link |
---|---|
US (3) | US6987171B1 (en) |
EP (1) | EP0980390A2 (en) |
JP (1) | JP2002502244A (en) |
AU (1) | AU8432498A (en) |
DE (1) | DE19722888A1 (en) |
WO (1) | WO1998054225A2 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040092718A1 (en) * | 2002-03-13 | 2004-05-13 | Thomas Hunig | Use of a CD28 binding substance for making a pharmaceutical composition |
US20040247594A1 (en) * | 2000-10-11 | 2004-12-09 | Thomas Hunig | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28 |
US20060039909A1 (en) * | 1997-05-28 | 2006-02-23 | Thomas Hunig | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
US20060121021A1 (en) * | 2002-07-04 | 2006-06-08 | Tegenero Ag, A German Corporation | Microparticle with cd28-specific monoclonal antibodies |
US20070154468A1 (en) * | 1999-08-13 | 2007-07-05 | Thomas Huenig | Use of CD28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
US20090104190A1 (en) * | 2003-03-21 | 2009-04-23 | John Wijdenes | Humanized anti-cd4 antibody with immunosuppressive properties |
US20110059084A1 (en) * | 2008-03-13 | 2011-03-10 | Frank Osterroth | Agent for treating disease |
US20110059082A1 (en) * | 2008-03-13 | 2011-03-10 | Matthias Germer | Agent for treating disease |
US20110059083A1 (en) * | 2008-03-13 | 2011-03-10 | Silke Aigner | Agent for treating disease |
US20110229465A1 (en) * | 2008-09-29 | 2011-09-22 | Frank Osterroth | Composition for treating disease |
WO2011126079A1 (en) | 2010-04-07 | 2011-10-13 | 株式会社日本触媒 | Method for producing water absorbent polyacrylic acid (salt) resin powder, and water absorbent polyacrylic acid (salt) resin powder |
WO2012144595A1 (en) | 2011-04-20 | 2012-10-26 | 株式会社日本触媒 | Process and apparatus for producing water-absorbable resin of polyacrylic acid (salt) type |
WO2013002387A1 (en) | 2011-06-29 | 2013-01-03 | 株式会社日本触媒 | Polyacrylic acid (salt) water-absorbent resin powder, and method for producing same |
WO2015030130A1 (en) | 2013-08-28 | 2015-03-05 | 株式会社日本触媒 | Gel pulverization device, method for manufacturing polyacrylic acid (polyacrylate) superabsorbent polymer powder, and superabsorbent polymer powder |
WO2015030129A1 (en) | 2013-08-28 | 2015-03-05 | 株式会社日本触媒 | Gel pulverization device, method for manufacturing polyacrylic acid (polyacrylate) superabsorbent polymer powder, and superabsorbent polymer powder |
WO2016105542A2 (en) | 2014-12-24 | 2016-06-30 | Neximmune, Inc | Nanoparticle compositions and methods for immunotherapy |
US9995733B2 (en) | 2009-11-30 | 2018-06-12 | Biotest Ag | Agents for treating disease |
EP3995145A1 (en) | 2013-06-24 | 2022-05-11 | NexImmune, Inc. | Compositions and methods for immunotherapy |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7541184B2 (en) * | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
US20050226857A1 (en) * | 2001-06-01 | 2005-10-13 | Xcyte Therapies, Inc. | T cell therapy for the treatment of cachexia and chronic diseases |
AU2002357427A1 (en) | 2001-12-04 | 2003-06-17 | Tegenero Ag | Peptide or protein containing a c'-d loop of the cd28 receptor family |
DE10160516A1 (en) * | 2001-12-04 | 2003-06-12 | Tegenero Gmbh | New protein or peptide, useful for modulating T cell proliferation and raising therapeutic antibodies, contains the C'-D loop of a CD28 protein or its analog or mimic |
DE10345008A1 (en) * | 2003-09-22 | 2005-04-28 | Tegenero Ag | Using superagonist, CD28-specific monoclonal antibodies, or their mimics, for treatment and prevention of autoimmune inflammation and for immune system reconstitution |
EP1600164A3 (en) * | 2003-09-22 | 2006-05-17 | TeGenero AG | Use of a CD28 binding substance for the production of a pharmaceutical composition with dose-dependent efficacy |
DE10352900A1 (en) * | 2003-11-11 | 2005-06-16 | Tegenero Ag | Method of making pharmaceutical composition for treatment of illnesses associated with deficient costimulation ability of T-cells, employs superagonistic monoclonal antibody |
WO2006050949A2 (en) * | 2004-11-11 | 2006-05-18 | Tegenero Ag | Superagonistic anti-cd28 antibody |
US7585960B2 (en) | 2005-05-11 | 2009-09-08 | Theramab Gmbh | Nucleic acids encoding superagonistic anti-CD28 antibodies |
KR20170114420A (en) * | 2016-04-04 | 2017-10-16 | 삼성전자주식회사 | Electronic device and method for receiving user input thereof |
AU2017370942A1 (en) | 2016-12-07 | 2019-06-13 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20210355216A1 (en) | 2018-10-05 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
KR20210095165A (en) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | Methods and devices for treating diseases with biopharmaceuticals |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2023198851A1 (en) | 2022-04-14 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558864A (en) * | 1991-03-06 | 1996-09-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1553168A3 (en) * | 1993-06-04 | 2011-04-06 | The United States of America as represented by The Secretary of The Navy | Methods for selectively stimulating proliferation of T cells |
EP0787188A1 (en) * | 1994-11-01 | 1997-08-06 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable t h?-independent cytotoxic t cells |
DE19722888A1 (en) * | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human CD28 specific monoclonal antibodies for antigen-unspecific activation of T lymphocytes |
-
1997
- 1997-05-28 DE DE19722888A patent/DE19722888A1/en not_active Ceased
-
1998
- 1998-05-28 AU AU84324/98A patent/AU8432498A/en not_active Abandoned
- 1998-05-28 EP EP98934848A patent/EP0980390A2/en not_active Ceased
- 1998-05-28 WO PCT/DE1998/001499 patent/WO1998054225A2/en active Application Filing
- 1998-05-28 JP JP50010899A patent/JP2002502244A/en active Pending
-
1999
- 1999-11-24 US US09/449,077 patent/US6987171B1/en not_active Expired - Fee Related
-
2004
- 2004-12-23 US US11/019,530 patent/US20060039909A1/en not_active Abandoned
-
2010
- 2010-04-08 US US12/756,665 patent/US8334102B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5558864A (en) * | 1991-03-06 | 1996-09-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric anti-epidermal growth factor receptor monoclonal antibodies |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
Non-Patent Citations (2)
Title |
---|
Siefken et al. Cell. Immnol. Feb. 1997; 176:59-65. * |
Tacke et al. Eur. J. Immunol. Jan. 1997; 27:239-247. * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8334102B2 (en) | 1997-05-28 | 2012-12-18 | Theramab Llc | Human CD28 specific monoclonal antibodies for antigen-nonspecific activation of T-lymphocytes |
US20060039909A1 (en) * | 1997-05-28 | 2006-02-23 | Thomas Hunig | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes |
US20110009602A1 (en) * | 1997-05-28 | 2011-01-13 | Thomas Hunig | Human cd28 specific monoclonal antibodies for antigen-nonspecific activation of t-lymphocytes |
US20110059071A1 (en) * | 1999-08-13 | 2011-03-10 | Thomas Huenig | Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
US20070154468A1 (en) * | 1999-08-13 | 2007-07-05 | Thomas Huenig | Use of CD28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
US20150150968A1 (en) * | 1999-08-13 | 2015-06-04 | Theramab Llc | Use of cd28-specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections |
US20040247594A1 (en) * | 2000-10-11 | 2004-12-09 | Thomas Hunig | Use of cd28-specific monoclonal antibodies for stimulating blood cells that lack cd28 |
US20090246204A1 (en) * | 2002-03-13 | 2009-10-01 | Tegenero Ag | Use of a cd28 binding substance for making a pharmaceutical composition |
US8389016B2 (en) | 2002-03-13 | 2013-03-05 | Theramab Llc | Use of a CD28 binding substance for making a pharmaceutical composition |
US20070134240A1 (en) * | 2002-03-13 | 2007-06-14 | Thomas Hunig | Use of a CD28 binding substance for making a pharmaceutical composition |
US20040092718A1 (en) * | 2002-03-13 | 2004-05-13 | Thomas Hunig | Use of a CD28 binding substance for making a pharmaceutical composition |
US7868143B2 (en) * | 2002-07-04 | 2011-01-11 | Theramab Llc | Microparticle with cd28-specific monoclonal antibodies |
US20060121021A1 (en) * | 2002-07-04 | 2006-06-08 | Tegenero Ag, A German Corporation | Microparticle with cd28-specific monoclonal antibodies |
US20100291676A1 (en) * | 2003-03-21 | 2010-11-18 | John Wijdenes | Humanized anti-cd4 antibody with immunosuppressive properties |
US8685651B2 (en) | 2003-03-21 | 2014-04-01 | Biotest Ag | Method for screening for an anti-CD4 antibody suitable for use in immunotherapy |
US9758581B2 (en) | 2003-03-21 | 2017-09-12 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US20090104190A1 (en) * | 2003-03-21 | 2009-04-23 | John Wijdenes | Humanized anti-cd4 antibody with immunosuppressive properties |
US8673304B2 (en) | 2003-03-21 | 2014-03-18 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US8586715B2 (en) | 2003-03-21 | 2013-11-19 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US8440806B2 (en) | 2003-03-21 | 2013-05-14 | Biotest Ag | Humanized anti-CD4 antibody with immunosuppressive properties |
US20090208497A1 (en) * | 2003-03-21 | 2009-08-20 | John Wijdenes | Humanized anti-cd4 antibody with immunosuppressive properties |
US20090208496A1 (en) * | 2003-03-21 | 2009-08-20 | John Wijdenes | Humanized anti-cd4 antibody with immunosuppressive properties |
US9334325B2 (en) | 2008-03-13 | 2016-05-10 | Biotest Ag | Method for treating psoriasis |
US9550831B2 (en) | 2008-03-13 | 2017-01-24 | Biotest Ag | Method for treating psoriasis |
US20110059082A1 (en) * | 2008-03-13 | 2011-03-10 | Matthias Germer | Agent for treating disease |
US20110059083A1 (en) * | 2008-03-13 | 2011-03-10 | Silke Aigner | Agent for treating disease |
US20110059084A1 (en) * | 2008-03-13 | 2011-03-10 | Frank Osterroth | Agent for treating disease |
US9512226B2 (en) | 2008-03-13 | 2016-12-06 | Biotest Ag | Agent for treating disease |
US20110229465A1 (en) * | 2008-09-29 | 2011-09-22 | Frank Osterroth | Composition for treating disease |
US9995733B2 (en) | 2009-11-30 | 2018-06-12 | Biotest Ag | Agents for treating disease |
WO2011126079A1 (en) | 2010-04-07 | 2011-10-13 | 株式会社日本触媒 | Method for producing water absorbent polyacrylic acid (salt) resin powder, and water absorbent polyacrylic acid (salt) resin powder |
EP3115382A1 (en) | 2010-04-07 | 2017-01-11 | Nippon Shokubai Co., Ltd. | Method for producing water absorbent polyacrylic acid (salt) resin powder, and water absorbent polyacrylic acid (salt) resin powder |
WO2012144595A1 (en) | 2011-04-20 | 2012-10-26 | 株式会社日本触媒 | Process and apparatus for producing water-absorbable resin of polyacrylic acid (salt) type |
WO2013002387A1 (en) | 2011-06-29 | 2013-01-03 | 株式会社日本触媒 | Polyacrylic acid (salt) water-absorbent resin powder, and method for producing same |
EP3995145A1 (en) | 2013-06-24 | 2022-05-11 | NexImmune, Inc. | Compositions and methods for immunotherapy |
WO2015030129A1 (en) | 2013-08-28 | 2015-03-05 | 株式会社日本触媒 | Gel pulverization device, method for manufacturing polyacrylic acid (polyacrylate) superabsorbent polymer powder, and superabsorbent polymer powder |
WO2015030130A1 (en) | 2013-08-28 | 2015-03-05 | 株式会社日本触媒 | Gel pulverization device, method for manufacturing polyacrylic acid (polyacrylate) superabsorbent polymer powder, and superabsorbent polymer powder |
EP3401070A1 (en) | 2013-08-28 | 2018-11-14 | Nippon Shokubai Co., Ltd. | A water absorbent resin powder and an absorbent body |
EP3520978A1 (en) | 2013-08-28 | 2019-08-07 | Nippon Shokubai Co., Ltd. | Polyacrylic acid (polyacrylate) superabsorbent polymer powder |
EP3970748A1 (en) | 2014-12-24 | 2022-03-23 | NexImmune, Inc. | Nanoparticle compositions and methods for immunotherapy |
WO2016105542A2 (en) | 2014-12-24 | 2016-06-30 | Neximmune, Inc | Nanoparticle compositions and methods for immunotherapy |
Also Published As
Publication number | Publication date |
---|---|
US8334102B2 (en) | 2012-12-18 |
US20110009602A1 (en) | 2011-01-13 |
EP0980390A2 (en) | 2000-02-23 |
US20060039909A1 (en) | 2006-02-23 |
JP2002502244A (en) | 2002-01-22 |
WO1998054225A2 (en) | 1998-12-03 |
WO1998054225A3 (en) | 1999-03-25 |
DE19722888A1 (en) | 1998-12-03 |
AU8432498A (en) | 1998-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6987171B1 (en) | Human CD28 specific monoclonal antibodies for antigen-non-specific activation of T-lymphocytes | |
Torre-Amione et al. | A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. | |
US6635424B2 (en) | Method for generating libraries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules | |
KR100609444B1 (en) | Graft rejection suppressors | |
Pereira et al. | Ontogenic development and tissue distribution of V gamma 1-expressing gamma/delta T lymphocytes in normal mice. | |
DE69534528T2 (en) | MULTI-STAGE CASCADE INCREASE VACCINE | |
EP1017723B1 (en) | Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use | |
US5980892A (en) | Monoclonal antibodies reactive with defined regions of the T cell antigen receptor | |
Raghavachar et al. | T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. | |
CN110462040A (en) | The expression of polypeptide is adjusted by new gene switch expression system | |
US5096704A (en) | Method of treating eosinophilia | |
US20040092718A1 (en) | Use of a CD28 binding substance for making a pharmaceutical composition | |
KR20080089677A (en) | Modulation of nkg2d | |
US10973895B2 (en) | Use of antibodies for enrichment of engineered T cells with exogenous immune receptors and antibodies for use in depletion of engineered T cells | |
JPH10502372A (en) | Methods of modulating T cell responses by manipulating a common cytokine receptor gamma chain | |
DE19939653A1 (en) | Use of CD28 specific monoclonal antibodies for the production of a pharmaceutical composition | |
Guglielmi et al. | Phenotypic changes of phytohaemagglutinin-stimulated hairy cells | |
US20240245771A1 (en) | Fully human antibody for human b7h3, chimeric antigen receptor and uses thereof | |
CA2134083C (en) | Prophylactic and therapeutic agents for autoimmune diseases | |
Palacios et al. | Monoclonal antibodies specific for interleukin 3-sensitive murine cells. | |
WO1996020206A9 (en) | Secreted human fas antigen | |
Trentin et al. | Expression and functional role of the p75 interleukin 2 receptor chain on leukemic hairy cells | |
US5229494A (en) | Receptor for natural killer and non-specific cytotoxic cells | |
AU4691796A (en) | Secreted human fas antigen | |
Couser et al. | Summary report: National Institutes of Health conference on monoclonal antibodies in renal research |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TEGENERO GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HUNIG, THOMAS;REEL/FRAME:011651/0960 Effective date: 20010125 |
|
AS | Assignment |
Owner name: TEGENERO AG, GERMANY Free format text: MERGER;ASSIGNOR:TEGENERO GMBH;REEL/FRAME:014771/0357 Effective date: 20030406 |
|
AS | Assignment |
Owner name: TEGENERO AG, GERMANY Free format text: RE-SUBMISSION OF ASSIGNMENT RECORDATION DOCUMENT ID NO. 102447411;ASSIGNOR:TEGENERO GMBH;REEL/FRAME:014974/0780 Effective date: 20020724 |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: THERAMAB GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEGENERO AG;REEL/FRAME:022902/0938 Effective date: 20081124 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: THERAMAB LLC, RUSSIAN FEDERATION Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THERAMAB GMBH;REEL/FRAME:023393/0825 Effective date: 20090920 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.) |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.) |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20180117 |